DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Chris Viehbacher - 3 Biogen - 2 Leqembi - 2 FactSet - 1 LSEG - 1 Eli Lilly - 1 drugmaker Biogen - 1 Eli Lilly's - 1
Top related locs:
U.S Indianapolis
Top related orgs:
LSEG - 1 Food and Drug Administration - 1 Drug Administration - 1 Alzheimer's Association - 1 FDA - 1 Club - 1 GE Healthcare - 1 FactSet - 1

Search resuls for: "Chris Viehbacher"


5 mentions found


☆ Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
  + stars: | 2024-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Biogen on Wednesday reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected. Biogen and Eisai 's Leqembi became the first drug found to slow the progression of Alzheimer's disease to win approval in the U.S. in July. Leqembi brought in about $19 million in sales for the quarter, up from the $10 million the drug generated last year. In February, Biogen CEO Chris Viehbacher told reporters that there were around 2,000 patients currently on Leqembi. Adjusting for one-time items, the company reported earnings of $3.67 per share.
Persons: Biogen, Leqembi, FactSet, Chris Viehbacher, LSEG Organizations: LSEG Locations: U.S
☆ What Eli Lilly investors can learn from the slow launch of a competitor's drug
  + stars: | 2024-02-15 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +8 min
Club holding Eli Lilly is expecting to get approval for its Alzheimer's treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. The FDA's decision on Lilly's drug, known as donanemab, is expected by the end of March. In the meantime, Eli Lilly's diabetes and obesity drugs, the heart of our investment thesis, should continue to fuel the lion's share of the company's topline growth. About 2,000 patients are currently taking Leqembi, Biogen said Tuesday, up from 800 at the time of the company's third-quarter report in November. LLY YTD mountain Eli Lilly's stock performance so far in 2024.
Persons: Eli Lilly, drugmaker Biogen, Eli Lilly's, —, Lilly, Biogen, Japan's, Chris Viehbacher, Viehbacher, Morgan Stanley, Lilly's, Donanemab, Mounjaro, Jim Cramer, Leqembi, Jim Cramer's, Jim Organizations: Food and Drug Administration, Drug Administration, Alzheimer's Association, FDA, Club, GE Healthcare, FactSet, Pharmaceutical, CNBC Locations: Indianapolis
☆ Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch
  + stars: | 2023-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Biogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved Alzheimer's drug Leqembi. It's the latest round of layoffs after Biogen slashed nearly 900 jobs last year. The larger plan is expected to generate approximately $1 billion in gross operating expense savings by 2025, according to Biogen. About $300 million of those savings will be reinvested into product launches and R&D programs. "There's a need, obviously, to have a strong investment in our new product launches.
Persons: Chris Viehbacher, Wells, Mohit Bansal
☆ FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
  + stars: | 2023-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
The Food and Drug Administration on Tuesday granted accelerated approval for Biogen 's drug tofersen, which treats a rare and aggressive form of the disease known as ALS. Accelerated approval is an FDA designation that clears drugs faster if they fill an unmet medical need for serious conditions. If a subsequent trial confirms those benefits, the FDA can grant traditional approval for the drug. An independent panel of advisors to the FDA last month similarly voted that tofersen's effect on neurofilament could produce a clinical benefit in ALS patients. Stephanie Fradette, Biogen's head of ALS development, said those SOD1 protein levels are "indirect evidence" that tofersen targets the rare form of ALS.
☆ Biogen Boss Turns Corner on Alzheimer’s Miscues
  + stars: | 2023-02-15 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
After botching the commercialization of its first Alzheimer’s drug, Biogen got a new lease on life with a second one that surprised skeptics of the amyloid hypothesis. The positive news restored investor excitement for its growth potential and allowed the Boston-area biotech to recruit the veteran Chris Viehbacher as its new boss. Now, he is trying to convince investors he can right the ship. That starts with not messing up the rollout of Alzheimer’s drug Leqembi. Mr. Viehbacher has shown he is intent on doing that by, first and foremost, maintaining a good relationship with lead partner Eisai Co Ltd.
0 next >>
Total: 5